SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Kaplan who wrote (4062)5/10/1998 7:32:00 PM
From: Bradpalm1  Read Replies (1) of 7041
 
Linda,

I believe that Vivus will be fighting an uphill battle against Viagra and Pfizer from this point forth. Coupled with their poor management, I believe that Vivus will founder in these turbulent ED seas.

The only legitimate oral alternatives to Viagra that I see on the horizon are the possible release of apomorphine by TAP and the eventual release of ICOS' second-generation Type 5 PDE inhibitor (similar to sildenafil) which is in Phase II trials in Europe.

I further believe that the submission of Vasomax' NDA is forthcoming but that the FDA, despite pressure applied by SGP, will reject further consideration of the application once it's reviewed by the Advisory Committee.

BTW, Claud and Dauntless seem to be different sides of the same coin.

Bradpalm1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News